Improving Healthspan and Increasing Lifespan
Phoenix SENOLYTIX™ is an affiliate of SENOTHERAPEUTIX, Inc.
Aging is the primary risk factor for chronic diseases, including cancer, Alzheimer’s Disease, diabetes, osteoarthritis, macular degeneration, along with many others. Gerotherapeutics aim to target aging’s underlying biological processes to extend healthspan and reduce healthcare burdens. It has been said that a successful gerotherapeutic would have a value that is too high to calculate — it instantly would become the most valuable medical intervention in history because of the number of person-years of healthy life that could be manufactured.
Phoenix SENOLYTIX is a longevity company using advanced technologies to develop novel gene therapies targeting the fundamental mechanisms of aging. Its lead programs are based on it’s two novel gene therapy platforms, ApoptiCIDe-CE™, our purposeful cell elimination gene therapy platform, and ApoptiCIDe-RGT™, our regulated gene therapy platform. Both utilize our proprietary enhanced, cell elimination switch technology that we originally developed as CaspaCIDe™ , as founders of Bellicum Pharmaceuticals, for use in T cells.
CaspaCIDe™ remains the world’s most utilized, clinically validated cell therapy safety switch, designed to be used only sporadically in the advent of a severe uncontrolled cell therapy toxicity. It has successfully been used to control toxicities in CAR cell therapy-treated patients experiencing CRS and the difficult-to-manage ICANS ~ 10 to 12 times in different settings by different investigators with 100% success rate. ApoptiCIDe™ is our re-imagined, proprietary version of CaspaCIDe™ that utilizes the same iCasp9 rimiducid-triggered switch as CaspaCIDe™, but replaces Bellicum’s intravenous rimiducid formulation with Phoenix’s proprietary SQ/IM rimiducid formulation as its wholly owned small molecule dimer “trigger” for ApoptiCIDe™.
Rimiducid was formulated by Bellicum Pharmaceuticals, Inc., for use with their cell therapy safety switch, CaspaCIDe™, under their IND, as a 40-mg infusion (5 mg/ml x 8 mL (25% Solutol HS15) into 100 mL saline), administered over 2 hours in a monitored infusion center. This IV infusion remains cumbersome and costly, and its excipient, Solutol HS15, itself, is associated with infusion reactions. Phoenix’s proprietary, reformulated rimiducid, PTC-1202, is convenient as either a simple and quick intramuscular (IM) or subcutaneous (SC) injection, and may potentially be further formulated into an autoinjector pen format.
Our lead products include ApoptiCIDe-CE-GERO-001™️, based on modifications of the gene regulatory elements from the p16Ink4a-ATTAC mouse model of genomic ablation of senescent cells, targeting senescent cells throughout the body for purposeful cell elimination for aging related disorders and ApoptiCIDe-CE-WAT-001™️, targeting adipocytes for purposeful cell elimination as a more immediate and effective method of eliminating fat without affecting lean body or bone mass for patients with morbid- or sarcopenic-obesity.
We have also developed ApoptiCIDe-RGT-Klotho™️ as the prototype Proof of Concept of our ApoptiCIDe-RGT™ regulated gene therapy platform that demonstrates our ability to reduce or eliminate the production of a gene-therapy delivered-protein or -antibody therapeutic within hours of administration of PTC-1202. This safer, regulated gene therapy platform technology is available for out-license.
In 2017, SENOTHERAPEUTIX, Inc. was founded in Houston, TX focused on developing gerotherapeutics to improve healthspan and increase lifespan. The Company’s dramatic discoveries and innovative technologies in the fields of geroscience and longevity medicine, have been spun out into three wholly owned subsidiaries of SENOTHERAPEUTIX, Inc.: (1) Eos SENOLYTIX, a longevity company developing novel gerotherapeutic, or “geropeptides”, to improve healthspan and increase lifespan (2) Perseus SENOLYTIX, an oncology company developing novel geropeptides to target cancer via this same novel mechanism as a potentially safe and effective new class of cancer therapeutics and (3) Phoenix SENOLYTIX, developing novel, controllable gene therapies utilizing our proprietary ApoptiCIDe-CE™ purposeful cell elimination platform to improve healthspan and increase lifespan. Visit our affiliate Companies to learn more about them!
